KR920703035A - Injection gas mixtures and their use in pharmaceutical formulations - Google Patents

Abstract

No content

Description

Injection gas mixtures and their use in pharmaceutical formulations

[Brief Description of Drawings]

Since this is an open matter, no full text was included.

Claims (13)

Propellent comprising at least two partially fluorinated lower alkanes and optionally at least two components containing at least one compound selected from the group consisting of TG l1, TG 12, TG l14, lower alkanes and DME gas mixture). The compound of claim 1, wherein the partially fluorinated lower alkanes are 1,1-difluoroethane, 1,1,1,2-tetrafluoroethane, pentafluoroethane and 1,1,1,2,3, Injection gas mixture wherein the lower alkanes are propane, butane or pentane, the compound selected from the group comprising 3,3-heptafluoropropane. The injection gas mixture of claim 1 further comprising at least one interfacial-active material. 3. The injection gas mixture of claim 2 wherein the interfacial-active material is a sorbitan ester with phospholipids, saturated or unsaturated higher fatty acids, or preferably polyethoxysorbitan esters with unsaturated higher fatty acids. 3. The injection gas mixture of claim 2 wherein the interfacial-active material is lecithin, polyethoxyethylene sorbitanate or sorbitan trioleate. Based on the injection gas mixture according to any one of claims 1 to 4, characterized in that the active substance contains betamimatics, choline inhibitors, steroids, allergic inhibitors or PAF-antagonists or combinations of these compounds. Pharmaceutical formulations for producing powdered aerosols. The method according to claim 5, wherein the beta-mematics used are bambuterol, bitolterol, cabuterol, clenbuterol, phenoterol, hexoprelinin, ibuterol, pirbuterol, procaterol, leproterol, salmeterol , Sulfonterol, tetrabutalin, tolubuterol, 1- (2-fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] Ethanol, erythro-5'-hydroxy-8 '-(1-hydroxy-2-isopropylaminobutyl) -2H-1,4-benzoxazin-3- (4H) -one, 1- (4- Amino-3-chloro-5-trifluoromethylphenyl) -2-tert-butylamino) ethanol, 1- (4-ethoxycarbonylamino-3-cyano-5-fluorophenyl) -2- ( Tert-butylamino) ethanol; Cholinergic agents used are ipratropium bromide, oxytropium bromide, romide, tropium chloride, benzyl acid-N-β-fluoroethyl nortropin, ester methobromide; The steroids used were budesonide, beclomethasone (or 17, 21-dipropionate thereof), dexamethasone-21-isonicotinate, flunisolid; Allergic inhibitors are disodium chromoglycate, nedochromyl; Pharmaceutical formulation wherein the PAF-antagonist is WEB 2086, WEB 2170, WEB 2347. The pharmaceutical formulation of claim 5, wherein the combination of actives comprises one of the betamimatics as defined in claim 6 and one of the anticholinergic agents as defined in claim 6. 6. A pharmaceutical formulation according to claim 5, wherein the combination of actives comprises one of the betamimatics specified in claim 6 and disodium chromoglycate. The pharmaceutical formulation of claim 5, wherein the combination of actives comprises one of the betamimatics as defined in claim 6 and one of the PAF-antagonists as defined in claim 6. The pharmaceutical formulation of claim 5, wherein the combination of actives comprises disodium chromoglycate and one of the PAF-antagonists as defined in claim 6. 7. A process according to any one of claims 5 to 10, characterized in that the pharmaceutically active substance atomised by conventional methods is suspended in a liquefied injection gas mixture according to any one of claims 1 to 4. Methods of Making Pharmaceutical Formulations. ※ Note: The disclosure is based on the initial application.